A randomized, double-blinded, placebo-controlled, single-center, comparative study evaluating Phaseolean® safety and...

Area of Science:

• Nutritional Science
• Pharmacology

Background:

• Phaseolean® is a standardized extract from Phaseolus vulgaris (white kidney bean) with demonstrated alpha-amylase inhibitory properties.
• This property aids weight management by delaying carbohydrate digestion and reducing calorie absorption.

Purpose of the Study:

• To evaluate the safety and efficacy of Phaseolean® for weight management in overweight or obese individuals.
• To compare the effects of two different doses of Phaseolean® against a placebo.

Main Methods:

• A randomized, double-blind, placebo-controlled study involving 66 overweight or obese participants.
• Participants received either 1500 mg/day Phaseolean®, 3000 mg/day Phaseolean®, or placebo for 45 days.
• Key metrics included body weight, BMI, body fat, skinfold thickness, and circumferences (waist, hip, thigh).

Main Results:

• Phaseolean® at 1500 mg/day resulted in an average weight loss of 2.10 kg, and 3000 mg/day resulted in 1.94 kg, significantly more than the placebo (0.13 kg) (p < 0.01).
• Significant reductions in BMI, body fat, skinfold thickness, and circumferences were observed in both Phaseolean® groups compared to placebo (p < 0.01).
• The 1500 mg/day dose demonstrated greater efficacy in weight reduction than the 3000 mg/day dose.

Conclusions:

• Phaseolean® is safe and effective for supporting weight management in overweight or obese individuals.
• The 1500 mg/day dosage of Phaseolean® appears optimal for weight reduction.
• The extract's alpha-amylase inhibitory action contributes to its weight management benefits.